Arcellx updates anito-cel data: Phase 1 median PFS 30.2 months; iMMagine-1 95% ORR

Arcellx, Inc.

Phase 1 study (38 patients): 100% ORR, 79% CR/sCR, median PFS 30.2 months at 38.1 months median follow-up; median OS not reached.
iMMagine-1 (58 patients): 95% ORR, 62% CR/sCR, median follow-up 10.3 months; 92% MRD negativity at 10^-5.
No delayed neurotoxicities (no parkinsonism, no cranial nerve palsies, no Guillain-Barré) observed across >140 patients dosed.
First patient dosed in iMMagine-3 study (earlier lines); manufactured by Kite with turnaround time in line with Kite's commercial products.
Data to be presented at ASH Annual Meeting Dec 7-10, 2024; company webcast Dec 9 at 8:30 p.m. PT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.